Rosiglitazone gives better glycaemic control, but at a cost
Rosiglitazone achieves slightly better long-term glycaemic control in patients with type 2 diabetes than vildagliptin, but at the cost of increased weight, less favourable lipid profile, and higher risk for peripheral oedema.
A US study found 600 patients randomised to either rosiglitazone 8mg a day or vildagliptin 100mg a day showed a similar average reduction in HbA1c of 1.55% and 1.24% respectively.
But those taking rosiglitazone gained a significant 4.67kg more over the two year study period, had a 6.5% higher risk of peripheral oedema, and experienced 3.4% more serious adverse events than those in the vildagliptin group.
Diabetes Obes Metab 2009;11:571-578.